5.9 million people, full EU CTR/CTIS integration, the world's oldest national cancer registry, a pharma ecosystem anchored by Novo Nordisk, Lundbeck, and Genmab, and lifetime health registers linking every citizen; Denmark is Northern Europe's most pharma-rich research platform.
Denmark is a Nordic constitutional monarchy of approximately 5.9 million people, comprising the Jutland peninsula and approximately 443 islands; including the major islands of Zealand (home to Copenhagen) and Funen (home to Odense). An EU member since 1973, one of the Union's most experienced and longest-standing members, Denmark retains the Danish Krone (DKK) pegged tightly to the Euro, removing effective currency risk while maintaining monetary sovereignty. Copenhagen is the capital, the dominant research hub, and home to the critical mass of Danish pharmaceutical and biomedical innovation; including the global headquarters of Novo Nordisk, Lundbeck, Leo Pharma, and Genmab within a 30-minute radius of the city centre. The Øresund Bridge physically connects Copenhagen to Malmö, Sweden, anchoring the cross-border Medicon Valley life sciences cluster; one of Europe's top five life sciences regions by company count and research output, spanning both Danish and southern Swedish academic and hospital infrastructure. Aarhus, Denmark's second city, hosts the country's second major academic university hospital. Odense and Aalborg anchor clinical research capacity in southern and northern Jutland respectively.
Clinical trials are regulated by the Danish Medicines Agency (Lægemiddelstyrelsen; DKMA), Denmark's national competent authority, operating under the full EU CTR/CTIS framework and participating actively in EMA scientific committee work. Ethics review is provided through Denmark's established system of regional scientific ethics committees coordinated at the national level under the National Committee on Health Research Ethics (DNVK), with EU CTR Part II review integrated into this framework. The Danish Health Data Authority (Sundhedsdatastyrelsen) manages Denmark's extraordinary national health register infrastructure; the backbone of Denmark's global research reputation; and provides the data access framework through which researchers and, where appropriate, sponsors can link trial data to national register outcomes. The density of major pharmaceutical companies headquartered in Denmark for a nation of 5.9 million is extraordinary: Novo Nordisk, Lundbeck, Leo Pharma, Genmab, Zealand Pharma, Bavarian Nordic, and others collectively create a pharmaceutical research ecosystem whose scale relative to national population has no equivalent in Northern Europe.
Denmark's population is approximately 80% Danish-origin, with Turkish (~1.5%), Polish (~1.2%), Syrian (~1.2%), and other growing communities; including significant immigrant populations in Copenhagen's diverse metropolitan districts that add ethnic enrollment variety to capital-region trial sites. Literacy approaches 99% and English proficiency is exceptional; Danish investigators, clinical staff, and trial administrators routinely communicate, publish, and collaborate in English as a matter of routine professional life, making Danish sites among the most operationally seamless for English-language sponsor teams of any European country. The healthcare system operates through five universal healthcare regions providing comprehensive primary and specialist care coverage, with digital health records increasingly interoperable across providers; a connectivity that, linked through the CPR number, creates the health data infrastructure described below. Median age is approximately 41–42 years, providing good enrollment depth across a broad range of therapeutic areas without the extreme population aging of Italy or Austria.
Denmark's disease burden carries several characteristics of clinical research significance. Cancer is a distinctive feature: Denmark has one of the highest cancer incidence rates in Europe; particularly in colorectal, breast, lung, and bladder cancers; driven by historically high smoking rates and alcohol consumption, but paired with increasingly good survival rates as early detection and treatment quality improve. This high incidence creates large, accessible cancer patient pools. Cardiovascular disease remains the leading cause of death (~33% of mortality). Mental health disorders; depression, bipolar disorder, schizophrenia; are well-characterised through the world's most comprehensive psychiatric register (active since 1969, capturing every psychiatric hospitalisation in Denmark) and have been central to landmark psychiatric genetics research through the iPSYCH (Initiative for Integrative Psychiatric Research) consortium. Metabolic disease, driven by rising obesity and Type 2 diabetes rates in the Danish population, is a major research priority anchored by the global density of metabolic disease expertise created by the Novo Nordisk ecosystem.
The Novo Nordisk effect; why Denmark is the world's metabolic disease research capital: Novo Nordisk, headquartered in Bagsværd outside Copenhagen, is not merely Denmark's largest company by market capitalisation; it is one of the world's top pharmaceutical companies and the global defining authority on diabetes, obesity, and GLP-1 receptor agonist pharmacology. The Novo Nordisk Foundation, one of the world's largest private foundations, channels billions of Danish Krone annually into Danish biomedical research infrastructure; including Steno Diabetes Center Copenhagen, the Novo Nordisk Foundation Center for Protein Research at the University of Copenhagen, and the Novo Nordisk Foundation Center for Basic Metabolic Research. The resulting investigator ecosystem around insulin resistance, Type 2 diabetes, obesity, fatty liver disease, GLP-1 biology, and cardiovascular-metabolic outcomes is genuinely without peer on any continent. For sponsors developing GLP-1, insulin, SGLT2, obesity, or metabolic syndrome programs, Danish sites offer patient populations, investigator depth, and mechanistic research infrastructure that no other country in the world replicates.
Denmark delivers two interlocking advantages that, combined, create a research platform of extraordinary scientific and operational depth: a pharmaceutical ecosystem; Novo Nordisk, Lundbeck, Leo Pharma, Genmab, and others; that has built world-leading investigator communities in metabolic disease, neuroscience, dermatology, and antibody oncology; and a national health register infrastructure built on the CPR number system that has been tracking every Danish citizen's health encounters, cancer diagnoses, prescriptions, and vital status since the 1940s through the 1970s. No other country of 5.9 million people runs both a global pharma cluster of this density and a health data register of this antiquity simultaneously.
Full EU CTR/CTIS integration since 1973 EU accession; DKMA as one of Europe's most experienced and respected NCAs; national ethics committee system (DNVK + regional committees) known for efficient and consistent review; Danish Health Data Authority providing register data access for outcome validation; Denmark frequently used as a lead member state for Nordic multinational CTIS submissions.
Register-based outcome ascertainment (mortality, cancer, cardiovascular events) through CPR-linked national databases eliminates long-term follow-up costs; primary endpoints automatically captured without patient contact; pharma HQ proximity (Novo Nordisk, Lundbeck, Leo in the Copenhagen corridor) reduces sponsor-site monitoring and administrative overhead; per-patient costs competitive within the Scandinavian/Nordic premium tier.
World's oldest cancer registry since 1943 providing 80+ years of continuous national cancer incidence data; comprehensive psychiatric register since 1969; most longitudinally deep psychiatric population data in the world; CPR-linked lifetime health record for every citizen enabling automatic long-term outcome ascertainment; metabolic disease patient depth from the Novo Nordisk ecosystem; high cancer incidence creating large treatment-eligible pools.
Novo Nordisk R&D campus (Bagsværd/Måløv) and Steno Diabetes Center for metabolic programs; Lundbeck CNS research infrastructure for psychiatric and neurological trials; Genmab antibody oncology capabilities; Rigshospitalet as nationally centralised flagship academic hospital; Medicon Valley cross-border cluster with direct bridge access to southern Swedish sites; SciLifeLab and Swedish biobank infrastructure reachable within 45 minutes of central Copenhagen.
Metabolic disease; diabetes, obesity, fatty liver disease, and cardiovascular-metabolic intersection; is Denmark's globally defining research pillar, built by Novo Nordisk's decades of Danish clinical trial investment and the Novo Nordisk Foundation's research infrastructure funding. Danish investigators in this area are the world's most experienced, and Steno Diabetes Center Copenhagen is the global reference institution for comprehensive diabetes care and research. Oncology constitutes Denmark's second major pillar, fuelled by the world's oldest cancer registry (since 1943) and the clinical research programs of Rigshospitalet, Aarhus University Hospital, and Genmab's antibody oncology pipeline. Neuroscience and psychiatry are Denmark's third major strength; Lundbeck's headquarters in Copenhagen have created the world's deepest investigator community for depression, schizophrenia, Alzheimer's, and other brain diseases, reinforced by the iPSYCH consortium's psychiatric genetics infrastructure and the world's most longitudinal psychiatric hospitalisation register. Dermatology, anchored by Leo Pharma's Copenhagen headquarters and the dermatology programme at Bispebjerg Hospital, is a distinctive fourth pillar. Cardiovascular disease, rare diseases, musculoskeletal conditions (driven by Nordic Bioscience), and the cross-cutting capability in pharmacoepidemiology and real-world evidence generation complete a portfolio of extraordinary breadth for a nation of 5.9 million.
Copenhagen and its surrounding Capital Region dominate Danish clinical research, accounting for the majority of Phase I–III trial volume through Rigshospitalet, the Herlev/Gentofte complex, Bispebjerg and Frederiksberg, and Hvidovre hospitals; all part of the Capital Region's Copenhagen University Hospital system. Steno Diabetes Center Copenhagen is a standalone global reference institution for metabolic research, not a general hospital but unmatched for its therapeutic focus. Aarhus University Hospital is the clear second academic anchor for all specialties across Jutland. Odense, Aalborg, and Vejle provide substantial Phase II–III capacity in southern and northern Jutland, with Vejle Hospital's oncology department particularly active in commercial cancer trial programs.
| # | Site | City | Notes |
|---|---|---|---|
| 01 | Rigshospitalet (Copenhagen University Hospital) | Copenhagen | Denmark's national hospital and the country's pre-eminent academic research institution; University of Copenhagen Faculty of Health affiliate; Phase I–IV across oncology, haematology, cardiology, neuroscience, infectious disease, rare diseases, and transplantation medicine; home of Denmark's leading Phase I oncology unit and the primary portal for international sponsors entering the Danish market; houses the largest concentration of specialist investigator depth in Scandinavia under one institution. |
| 02 | Rigshospitalet; Glostrup Campus | Glostrup | The Glostrup campus of Rigshospitalet, specialising in neuroscience, ophthalmology, and psychiatry; University of Copenhagen affiliate; Phase II–IV in neurological disorders, multiple sclerosis, psychiatric conditions, and ophthalmic diseases; home of Denmark's national multiple sclerosis centre; a key site for Lundbeck-partnered CNS program development and for sponsors targeting neurological and psychiatric patient populations through Copenhagen University Hospital infrastructure. |
| 03 | Copenhagen University Hospital; Herlev | Herlev | One of Denmark's most research-active hospitals and the oncology anchor of the Capital Region's Copenhagen University Hospital network; University of Copenhagen affiliate; Phase II–IV with exceptional depth in oncology; particularly breast cancer, gastrointestinal cancers, and haematologic malignancies; home of Denmark's national bowel cancer screening programme clinical coordination; one of the highest-enrolling oncology trial sites in Scandinavia with active EORTC and international cooperative group participation. |
| 04 | Steno Diabetes Center Copenhagen | Herlev | The world's most internationally recognised integrated diabetes research and treatment centre; established with Novo Nordisk Foundation support and operating within the Capital Region hospital system; Phase II–IV across Type 1 and Type 2 diabetes, obesity, diabetic complications, renal outcomes, and cardiovascular-metabolic indications; an indispensable site for any sponsor developing metabolic disease, GLP-1, insulin, SGLT2, or obesity programs; the investigator team here has been central to the clinical development of the modern diabetes pharmacopeia. |
| 05 | Bispebjerg and Frederiksberg Hospital | Copenhagen | A major Copenhagen University Hospital complex with distinctive specialisations in dermatology, pulmonology, and clinical pharmacology; University of Copenhagen affiliate; Phase II–IV with world-class depth in inflammatory skin diseases; the Department of Dermatology here is one of Europe's most active dermatology trial sites, driven by the proximity and partnership with Leo Pharma's Copenhagen headquarters; also active in respiratory Phase II–III programs and clinical pharmacology first-in-human studies. |
| 06 | Hvidovre Hospital (Copenhagen University Hospital; Amager and Hvidovre) | Hvidovre | A major metropolitan Copenhagen University Hospital serving the southern capital region; University of Copenhagen affiliate; Phase II–IV across internal medicine, infectious disease, gastroenterology, and hepatology; one of Denmark's leading sites for HIV and hepatitis research; nationally recognised for gastrointestinal and hepatology clinical trials including non-alcoholic fatty liver disease (NAFLD/MAFLD) programs where the Novo Nordisk research ecosystem creates strong local investigator interest. |
| 07 | Copenhagen University Hospital; Gentofte | Gentofte | A major university hospital campus serving northern Copenhagen; University of Copenhagen affiliate; Phase II–IV with particular depth in cardiology, rheumatology, and allergy; home of one of Denmark's most active cardiovascular research departments; geographically co-located with Novo Nordisk's headquarters in adjacent Bagsværd; creating a natural partnership intensity between Novo Nordisk's cardiovascular and metabolic disease clinical programs and the Gentofte cardiac investigator community. |
| 08 | Aarhus University Hospital | Aarhus | Denmark's second major academic hospital complex and the anchor research institution for all of Jutland; Aarhus University Faculty of Health affiliate; Phase I–IV across oncology, cardiovascular, haematology, neuroscience, endocrinology, and rare diseases; the most research-active hospital outside Copenhagen and a major Phase I oncology site in its own right; active in EORTC, ESC, and major international cooperative group networks; the natural partner for sponsors seeking Denmark-wide multi-site coverage combining Capital Region and Jutland patient populations. |
| 09 | Odense University Hospital (OUH) | Odense | Southern Denmark's university hospital and the primary clinical base of the University of Southern Denmark (SDU) Faculty of Health Sciences; Phase II–IV across oncology, cardiovascular, endocrinology, and internal medicine; an active participant in national and international oncology cooperative group programs; serves the Funen island and southern Jutland population; provides important geographical patient coverage for multi-site Danish trial designs requiring all-Denmark patient breadth beyond the Copenhagen-Aarhus corridor. |
| 10 | Aalborg University Hospital | Aalborg | Northern Jutland's primary academic hospital and the clinical base of Aalborg University Faculty of Medicine; Phase II–IV across oncology, cardiovascular, psychiatry, and internal medicine; a nationally recognised cardiac research programme and active psychiatric clinical trial portfolio reflecting the North Denmark psychiatric register research tradition; important regional node for sponsors seeking northern Jutland patient coverage and a full-Denmark trial footprint with register-linked outcome ascertainment. |
| 11 | Vejle Hospital | Vejle | Central Jutland's major hospital and one of Denmark's most oncology-active non-university trial sites; part of the Lillebælt Hospital group; Phase II–IV with particular strength in gastrointestinal, colorectal, and lung cancer trials; the Department of Oncology at Vejle has been consistently among Denmark's highest-enrolling oncology trial sites outside the university hospital network; an important Phase III enrollment anchor for sponsors requiring high-volume Jutland oncology patient access. |
| 12 | Zealand University Hospital (Sjællands Universitetshospital) | Roskilde | The primary academic hospital for the Zealand region; University of Copenhagen affiliate; Phase II–III across internal medicine, oncology, cardiovascular, and emergency medicine across its campuses in Roskilde and Køge; serves the large Zealand population outside Copenhagen that is well-covered by CPR-linked register infrastructure but would otherwise be underrepresented in Capital Region-only trial designs; growing research portfolio supporting the University of Copenhagen's regional clinical research expansion strategy. |
Denmark's national hospital and the country's pre-eminent academic research institution; University of Copenhagen Faculty of Health affiliate; Phase I–IV across oncology, haematology, cardiology, neuroscience, infectious disease, rare diseases, and transplantation medicine; home of Denmark's leading Phase I oncology unit and the primary portal for international sponsors entering the Danish market; houses the largest concentration of specialist investigator depth in Scandinavia under one institution.
The Glostrup campus of Rigshospitalet, specialising in neuroscience, ophthalmology, and psychiatry; University of Copenhagen affiliate; Phase II–IV in neurological disorders, multiple sclerosis, psychiatric conditions, and ophthalmic diseases; home of Denmark's national multiple sclerosis centre; a key site for Lundbeck-partnered CNS program development and for sponsors targeting neurological and psychiatric patient populations through Copenhagen University Hospital infrastructure.
One of Denmark's most research-active hospitals and the oncology anchor of the Capital Region's Copenhagen University Hospital network; University of Copenhagen affiliate; Phase II–IV with exceptional depth in oncology; particularly breast cancer, gastrointestinal cancers, and haematologic malignancies; home of Denmark's national bowel cancer screening programme clinical coordination; one of the highest-enrolling oncology trial sites in Scandinavia with active EORTC and international cooperative group participation.
The world's most internationally recognised integrated diabetes research and treatment centre; established with Novo Nordisk Foundation support and operating within the Capital Region hospital system; Phase II–IV across Type 1 and Type 2 diabetes, obesity, diabetic complications, renal outcomes, and cardiovascular-metabolic indications; an indispensable site for any sponsor developing metabolic disease, GLP-1, insulin, SGLT2, or obesity programs; the investigator team here has been central to the clinical development of the modern diabetes pharmacopeia.
A major Copenhagen University Hospital complex with distinctive specialisations in dermatology, pulmonology, and clinical pharmacology; University of Copenhagen affiliate; Phase II–IV with world-class depth in inflammatory skin diseases; the Department of Dermatology here is one of Europe's most active dermatology trial sites, driven by the proximity and partnership with Leo Pharma's Copenhagen headquarters; also active in respiratory Phase II–III programs and clinical pharmacology first-in-human studies.
A major metropolitan Copenhagen University Hospital serving the southern capital region; University of Copenhagen affiliate; Phase II–IV across internal medicine, infectious disease, gastroenterology, and hepatology; one of Denmark's leading sites for HIV and hepatitis research; nationally recognised for gastrointestinal and hepatology clinical trials including non-alcoholic fatty liver disease (NAFLD/MAFLD) programs where the Novo Nordisk research ecosystem creates strong local investigator interest.
A major university hospital campus serving northern Copenhagen; University of Copenhagen affiliate; Phase II–IV with particular depth in cardiology, rheumatology, and allergy; home of one of Denmark's most active cardiovascular research departments; geographically co-located with Novo Nordisk's headquarters in adjacent Bagsværd; creating a natural partnership intensity between Novo Nordisk's cardiovascular and metabolic disease clinical programs and the Gentofte cardiac investigator community.
Denmark's second major academic hospital complex and the anchor research institution for all of Jutland; Aarhus University Faculty of Health affiliate; Phase I–IV across oncology, cardiovascular, haematology, neuroscience, endocrinology, and rare diseases; the most research-active hospital outside Copenhagen and a major Phase I oncology site in its own right; active in EORTC, ESC, and major international cooperative group networks; the natural partner for sponsors seeking Denmark-wide multi-site coverage combining Capital Region and Jutland patient populations.
Southern Denmark's university hospital and the primary clinical base of the University of Southern Denmark (SDU) Faculty of Health Sciences; Phase II–IV across oncology, cardiovascular, endocrinology, and internal medicine; an active participant in national and international oncology cooperative group programs; serves the Funen island and southern Jutland population; provides important geographical patient coverage for multi-site Danish trial designs requiring all-Denmark patient breadth beyond the Copenhagen-Aarhus corridor.
Northern Jutland's primary academic hospital and the clinical base of Aalborg University Faculty of Medicine; Phase II–IV across oncology, cardiovascular, psychiatry, and internal medicine; a nationally recognised cardiac research programme and active psychiatric clinical trial portfolio reflecting the North Denmark psychiatric register research tradition; important regional node for sponsors seeking northern Jutland patient coverage and a full-Denmark trial footprint with register-linked outcome ascertainment.
Central Jutland's major hospital and one of Denmark's most oncology-active non-university trial sites; part of the Lillebælt Hospital group; Phase II–IV with particular strength in gastrointestinal, colorectal, and lung cancer trials; the Department of Oncology at Vejle has been consistently among Denmark's highest-enrolling oncology trial sites outside the university hospital network; an important Phase III enrollment anchor for sponsors requiring high-volume Jutland oncology patient access.
The primary academic hospital for the Zealand region; University of Copenhagen affiliate; Phase II–III across internal medicine, oncology, cardiovascular, and emergency medicine across its campuses in Roskilde and Køge; serves the large Zealand population outside Copenhagen that is well-covered by CPR-linked register infrastructure but would otherwise be underrepresented in Capital Region-only trial designs; growing research portfolio supporting the University of Copenhagen's regional clinical research expansion strategy.
These are the primary regulatory, academic, and industry bodies shaping Denmark's clinical research ecosystem.
Denmark's national competent authority for clinical trial regulation and pharmaceutical product oversight; one of Europe's most experienced and internationally respected NCAs; participates actively in EMA CHMP and other scientific committee work; responsible for Part I scientific review of Danish CTIS submissions; known for thorough, transparent regulatory dialogue with sponsors and efficient GCP inspection processes; a regulatory culture shaped by decades of partnership with Denmark's major pharmaceutical companies.
Denmark's national scientific ethics oversight body, coordinating with five regional scientific ethics committees to provide Part II review for clinical trials under EU CTR; operates under the Danish Act on Research Ethics Review of Health Research Projects; provides a nationally consistent ethical review standard and serves as the primary national authority for ethics committee appeals and interpretation; known for principled and efficient review processes within EU CTR timelines.
The governmental body managing Denmark's national health register infrastructure; including the Danish Cancer Registry (since 1943), National Patient Registry (since 1977), Psychiatric Central Research Register (since 1969), National Prescription Registry (since 1994), and Cause of Death Registry; responsible for research data access applications through which sponsors can, under appropriate ethics approvals, link trial data to national register outcomes; the institutional guardian of Denmark's irreplaceable register data assets.
Denmark's largest and most internationally prominent medical faculty; affiliated with Rigshospitalet, Herlev/Gentofte, Bispebjerg/Frederiksberg, Hvidovre, Gentofte, and Zealand University Hospital; produces the primary investigator pipeline for Danish clinical research; consistently ranked among Europe's top 20 medical research universities; major collaborative research partnerships with Novo Nordisk Foundation, Lundbeck Foundation, and all major Danish and international pharmaceutical companies.
Denmark's second major medical faculty, affiliated with Aarhus University Hospital and driving the investigator pipeline for all of Jutland's clinical research network; internationally recognised for epidemiology, register-based research, and population health sciences; the Aarhus cohort studies have produced foundational evidence in cardiovascular, psychiatric, and cancer epidemiology; a key partner for sponsors seeking investigator co-authorship and scientific design support for register-linked trial programs.
The world's most internationally recognised integrated diabetes research, treatment, and prevention centre; established with Novo Nordisk Foundation support as a national hub for comprehensive metabolic disease care and clinical investigation; runs an active Phase II–IV program in diabetes, obesity, diabetic kidney disease, and cardiovascular-metabolic outcomes; partners with Novo Nordisk, AstraZeneca, Eli Lilly, and other major diabetes franchise companies on pivotal trials; the essential investigator partner for any sponsor entering the metabolic disease clinical development space in Europe.
One of the world's largest private foundations by assets, channelling multi-billion-krone annual grants into Danish biomedical research infrastructure, university research centres, and hospital research programmes; a foundational funder of Steno Diabetes Center, the Novo Nordisk Foundation Center for Protein Research, the Novo Nordisk Foundation Center for Basic Metabolic Research (CBMR), and dozens of other Danish research institutions; the financial engine behind the Danish life sciences ecosystem's extraordinary depth relative to national population size.
Global CRO with Danish operations covering Phase I–IV trial management across metabolic disease, oncology, cardiovascular, and rare disease indications; DKMA/CTIS regulatory submission expertise; site monitoring and data management across Rigshospitalet, Aarhus University Hospital, and the Capital Region hospital network; register data linkage support for outcome ascertainment and pharmacoepidemiological sub-studies leveraging the Danish CPR infrastructure.
International CRO with Danish operations managing Phase I–IV oncology, metabolic disease, and CNS programs; established investigator relationships across Rigshospitalet, Steno Diabetes Center, Herlev Hospital, and Aarhus University Hospital; specialist early-phase and biomarker-driven trial capability in partnership with the Novo Nordisk ecosystem and Danish academic metabolic disease investigator community; deep DKMA regulatory expertise supporting CTIS submissions using Denmark as lead member state.
Global CRO with Danish operations providing Phase II–IV trial management and EU regulatory strategy; CTIS submission and DKMA interaction expertise for oncology, metabolic disease, and rare disease programs; established site networks across Copenhagen University Hospital and Aarhus University Hospital; supports sponsors adding Danish sites to existing EU-wide trial portfolios or seeking Denmark as a lead member state for Nordic multinational CTIS submissions.
A Danish-headquartered specialist biopharmaceutical research organisation with a globally recognised position in Phase II–III clinical trials for osteoporosis, arthritis, musculoskeletal diseases, and fibrosis; running trials and developing proprietary biomarkers for bone and connective tissue diseases; a distinctive Danish research support institution whose musculoskeletal disease trial expertise and biomarker development capabilities are internationally sought by major pharmaceutical companies for Phase II bone and joint indication programs.
Denmark combines EU-aligned regulation, lifetime CPR-linked health registers, exceptional English fluency, and one of Europe's strongest pharma ecosystems. With Novo Nordisk, Lundbeck, Leo Pharma, Genmab, Steno Diabetes Center, Rigshospitalet, and the wider Medicon Valley network, Denmark is especially valuable for metabolic disease, oncology, CNS, dermatology, and register-linked real-world evidence studies.
Keep exploring
Discover 11 early-phase clinical trials and design frameworks redefining development strategy in 2025-2026, and what sponsors can learn to reduce late-stage failure risk.
Four pervasive AI misconceptions in clinical trials that derail programs, inflate costs, and create regulatory exposure, with evidence on what the data actually shows.
Before selecting an AI patient screening tool for clinical trial recruitment, ask these 7 critical questions to avoid costly mismatches and protocol failures.
Accelerated Approval is an FDA pathway that allows earlier approval of drugs treating serious conditions and filling unmet medical need on the basis of a surrogate endpoint that is reasonably likely to predict clinical benefit, conditional on confirmatory post-marketing trials.